department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Prevymis · pharmadog

pharmadog
drugs
Prevymis

drug

patient view →

letermovir

Marketedupdated 2mo ago

by Merck Sharp & Dohme Corp (Inactive)

Approved

community read0 votes

all catalysts(1)

phase 2 completion · 1

phase 2 completion

Hematology Hospital of Chinese Academy of Medical Sciences — letermovir (Phase II Trial Completion)

News(0)

no news has mentioned this drug yet

brand

Prevymis

generic

letermovir

indication

Cytomegalovirus (HHV-5) Infections

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 2, 2026

26 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Feb 28, 2033formulationUS 10603384
Feb 28, 2033formulationUS 10603384
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y

FDA exclusivities (32)

Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031ODE-495Orphan Drug (7y)
Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031ODE-495Orphan Drug (7y)
Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031ODE-495Orphan Drug (7y)
Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031

ODE-495

Orphan Drug (7y)

Aug 30, 2031ODE-497Orphan Drug (7y)

Aug 30, 2031ODE-495Orphan Drug (7y)

Aug 30, 2031ODE-497Orphan Drug (7y)

Aug 30, 2031ODE-495Orphan Drug (7y)

Jun 5, 2030ODE-423Orphan Drug (7y)3.9y

Jun 5, 2030ODE-423Orphan Drug (7y)3.9y

Jun 5, 2030ODE-423Orphan Drug (7y)3.9y

Jun 5, 2030ODE-423Orphan Drug (7y)3.9y

Jun 5, 2030ODE*ODE*3.9y

Jun 5, 2030ODE*ODE*3.9y

Aug 30, 2027NPNP1.1y

Aug 30, 2027NPPNew Product (3y)1.1y

Aug 30, 2027NPPNew Product (3y)1.1y

Aug 30, 2027NPPNew Product (3y)1.1y

Aug 30, 2027NPPNew Product (3y)1.1y

Aug 30, 2027NPNP1.1y

Aug 2, 2026D-189New Indication (3y)26d

Aug 2, 2026D-189New Indication (3y)26d

Aug 2, 2026D-189New Indication (3y)26d

Aug 2, 2026D-189New Indication (3y)26d

Jun 5, 2026I-916Indication (3y)

Jun 5, 2026I-916Indication (3y)

Jun 5, 2026I-916Indication (3y)

Jun 5, 2026I-916Indication (3y)

🐶 often sniffed alongside

top 3

companyHematology Hospital of Chinese Academy of Medical Sciences1 co-mentions · 1 sources
tagHematology1 co-mentions · 1 sources
drugUndisclosed1 co-mentions · 1 sources

Trials studying letermovir

phase1A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)recruitingn=40
phase2Letermovir for CMV Prevention After Lung Transplantationcompletedn=15
phase3De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipientsactive not recruitingn=30
phase3Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipientsrecruitingn=90
phase2A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infectioncompletedn=102
phase1Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysisnot yet recruitingn=20
phase4Letermovir Use in Heart Transplant Recipientscompletedn=32
phase2Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipientsrecruitingn=80

more trials →